TARGET GCAT Registry

Status Terminated

Clinical Trial Summary

A longitudinal post-marketing surveillance registry nested within the UK GCA Consortium that assesses the effectiveness and safety of tocilizumab in controlling refractory or relapsing forms of GCA in patients who require escalation of therapy to reach sustained remission. Half the patients recruited will have been prescribed tocilizumab (cases) and the other half will be prescribed alternative therapies (controls). There are four study visits over 18 months: baseline, 6 months, 12 months and 18 months. At each visit data is collected on demographics; diagnosis and investigations; previous and concomitant medications; medical history; co-morbidities, vital signs; smoking and alcohol; disease activity and damage; routine laboratory tests; reason for starting escalation therapy. Safety data is collected on an ongoing basis.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04049071
Study type	Observational [Patient Registry]
Source	University of Leeds
Contact
Status	Terminated
Phase
Start date	May 13, 2019
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03812302` - Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA)	Phase 2
Recruiting	`NCT02257866` - Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Recruiting	`NCT04888221` - Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement	Phase 3
Recruiting	`NCT05380453` - Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission	Phase 3
Recruiting	`NCT02333708` - Study of Circulating Microparticles in Giant Cell Arteritis
Completed	`NCT01450137` - Tocilizumab for Patients With Giant Cell Arteritis	Phase 2
Completed	`NCT03827018` - KPL-301 for Subjects With Giant Cell Arteritis	Phase 2
Active, not recruiting	`NCT04519580` - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting	`NCT04239196` - Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA	Phase 2
Completed	`NCT03202368` - An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)	Phase 3
Not yet recruiting	`NCT06004154` - Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis) (EvHortim)
Not yet recruiting	`NCT02523625` - Giant Cell Arteritis: Improving Use of Ultrasound Evaluation	N/A
Completed	`NCT03285945` - FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment	N/A
Completed	`NCT02190916` - Vasculitis Illness Perception (VIP) Study	N/A
Recruiting	`NCT01241305` - One-Time DNA Study for Vasculitis
Terminated	`NCT02531633` - Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis	Phase 3
Completed	`NCT03409913` - Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA	N/A
Completed	`NCT03765424` - Evaluation of Ultrasound and PET/CT in the Diagnosis and Monitoring of Giant Cell Arteritis
Completed	`NCT01910038` - Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.	Phase 2
Not yet recruiting	`NCT04012905` - Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering	Phase 3